何军华.头孢哌酮钠舒巴坦钠的临床应用效果研究[J].实用中西医结合临床,2019,19(9): |
头孢哌酮钠舒巴坦钠的临床应用效果研究 |
Clinical application of cefoperazone sodium and sulbactam sodium |
投稿时间:2019-05-22 修订日期:2019-06-15 |
DOI: |
中文关键词: 头孢哌酮钠舒巴坦钠 感染 临床疗效 不良反应 |
英文关键词: cefoperazone sodium sulbactam sodium infection clinical efficacy adverse reactions |
基金项目: |
|
摘要点击次数: 668 |
全文下载次数: 207 |
中文摘要: |
目的:探讨头孢哌酮钠舒巴坦钠的临床应用效果。方法:选取2017.03~2018.03来我院就诊的108例需抗感染治疗的患者为研究对象,随机分为观察组和对照组,每组54例,观察组给予头孢哌酮钠舒巴坦钠滴注,对照组给予头孢他啶滴注,比较两组患者的临床疗效和不良反应发生情况。结果:观察组患者的临床有效率为94.44%(51/54),显著高于对照组的68.82%(37/54),差异有统计学意义,P<0.05;观察组患者不良反应发生率为37.03%(20/54),显著高于对照组的16.67%(9/54),差异有统计学意义,P<0.05。结论:头孢哌酮钠舒巴坦钠用于治疗感染疗效显著,但不良反应发生率较高,在临床应用过程中,需根据患者状况,谨慎给药。 |
英文摘要: |
Objective: To investigate the clinical application of cefoperazone sodium and sulbactam sodium. Methods: A total of 186 patients who needed anti-infective treatment from 2017.03~2018.03 were randomly divided into observation group and control group, 93 cases in each group. The observation group was given cefoperazone sodium and sulbactam sodium, and the control group was given ceftazidime. The clinical efficacy and adverse reactions of the two groups were compared. Results: The clinical effective rate was 94.62% (88/93) in the observation group, which was higher than 68.82% (64/93) in the control group. The difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 38.71% (36/93), which was higher than the control group of 15.05% (14/93), the difference was statistically significant, P <0.05. Conclusion: Cefoperazone sodium and sulbactam sodium is effective in the treatment of infection, but the incidence of adverse reactions is high. In clinical application, it should be administered cautiously according to the patient"s condition. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|